Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Martin Midstream Partners Announces Amendment To Revolving Credit Facility
Martin Midstream Partners Announces Amendment To Revolving Credit Facility


Martin Midstream Partners L.P. (NASDAQ:MMLP) (“MMLP”) announced today that its wholly owned subsidiary, Martin Operating Partnership L.P., as borrower, MMLP and certain of MMLP’s other

JetBlue Announces Fourth Quarter 2022 Results
JetBlue Announces Fourth Quarter 2022 Results


JetBlue Airways Corporation (NASDAQ: JBLU) today reported its financial results for the fourth quarter of 2022.



“Thanks to the outstanding efforts of JetBlue’s crewmembers, we closed the year

Blue Bird to Report Fiscal Year 2023 First Quarter Results on February 8, 2023
Blue Bird to Report Fiscal Year 2023 First Quarter Results on February 8, 2023


Blue Bird Corporation (Nasdaq: BLBD), the leader in electric and low-emission school buses, will release its fiscal year 2023 first quarter financial results on February 8, 2023.



The public is

EQS-News: Hapag-Lloyd AG acquires share in J M Baxi Ports & Logistics Limited
EQS-News: Hapag-Lloyd AG acquires share in J M Baxi Ports & Logistics Limited
EQS-News: Hapag-Lloyd AG acquires share in J M Baxi Ports & Logistics Limited
Martin Midstream Partners Announces Quarterly Cash Distribution
Martin Midstream Partners Announces Quarterly Cash Distribution


Martin Midstream Partners L.P. (NASDAQ: MMLP) announced it has declared a quarterly cash distribution of $0.005 per unit for the quarter ended December 31, 2022. The distribution is payable on

EQS-Adhoc: Logwin AG - Increase of distribution to shareholders in the year 2023
EQS-Adhoc: Logwin AG - Increase of distribution to shareholders in the year 2023
EQS-Adhoc: Logwin AG - Increase of distribution to shareholders in the year 2023
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
JetBlue Announces Record and Payment Dates for January 2023 Additional Prepayment to Spirit Stockholders
JetBlue Announces Record and Payment Dates for January 2023 Additional Prepayment to Spirit Stockholders


As previously announced, in connection with the Agreement and Plan of Merger, dated as of July 28, 2022 (the “Merger Agreement”), by and among JetBlue Airways Corporation (“JetBlue”) (NASDAQ

Group Strategic Review
Group Strategic Review
Group Strategic Review
JetBlue Announces Webcast of Fourth Quarter 2022 Earnings Conference Call
JetBlue Announces Webcast of Fourth Quarter 2022 Earnings Conference Call


JetBlue Airways Corporation (Nasdaq: JBLU) announced today that it will hold its quarterly conference call to discuss fourth quarter 2022 financial results on January 26th, 2023 at 10:00 a.m. ET.

EQS-News: Hapag-Lloyd acquires stake in the Spinelli Group
EQS-News: Hapag-Lloyd acquires stake in the Spinelli Group
EQS-News: Hapag-Lloyd acquires stake in the Spinelli Group
Director/PDMR Shareholding
Director/PDMR Shareholding
Director/PDMR Shareholding
Director/PDMR Shareholding
Director/PDMR Shareholding
Director/PDMR Shareholding
Notice of AGM
Notice of AGM
Notice of AGM
Directorate Change
Directorate Change
Directorate Change
EQS-News: Logwin AG: Federal Central Office establishes retribution of additional capital contribution for 2020 to 2022 distributions to German investors. Proceedings in Luxembourg still open.
EQS-News: Logwin AG: Federal Central Office establishes retribution of additional capital contribution for 2020 to 2022 distributions to German investors. Proceedings in Luxembourg still open.
EQS-News: Logwin AG: Federal Central Office establishes retribution of additional capital contribution for 2020 to 2022 distributions to German investors. Proceedings in Luxembourg still open.
Director/PDMR Shareholding
Director/PDMR Shareholding
Director/PDMR Shareholding
Awarded preferred bidder status for Alicante Cruise Port
Awarded preferred bidder status for Alicante Cruise Port
Awarded preferred bidder status for Alicante Cruise Port
EQS-Adhoc: SMT Scharf AG again raises revenue and earnings forecast for fiscal year 2022
EQS-Adhoc: SMT Scharf AG again raises revenue and earnings forecast for fiscal year 2022
EQS-Adhoc: SMT Scharf AG again raises revenue and earnings forecast for fiscal year 2022
Interim Results for six months to 30 September 2022
Interim Results for six months to 30 September 2022
Interim Results for six months to 30 September 2022
Blue Bird Reports Fiscal 2022 Fourth Quarter and Full Year Results; Record EV Sales and Backlog; Positioned for a Strong Recovery in Fiscal 2023
Blue Bird Reports Fiscal 2022 Fourth Quarter and Full Year Results; Record EV Sales and Backlog; Positioned for a Strong Recovery in Fiscal 2023


Blue Bird Corporation (“Blue Bird”) (Nasdaq: BLBD), the leader in electric and low-emission school buses, announced today its fiscal 2022 fourth quarter and full year results.



Highlights


(in

Director/PDMR Shareholding
Director/PDMR Shareholding
Director/PDMR Shareholding
Annual Report and Accounts
Annual Report and Accounts
Annual Report and Accounts
Blue Bird Teams Up with Highland Electric Fleets to Provide 12 Electric School Buses to Illinois School District
Blue Bird Teams Up with Highland Electric Fleets to Provide 12 Electric School Buses to Illinois School District


Blue Bird Corporation (Nasdaq: BLBD), the leader in electric and low-emission school buses, has teamed up with Highland Electric Fleets to make it simpler and more affordable for Hardin County

Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5